Momelotinib reduces transfusion requirements in patients with myelofibrosis

Ruben Mesa; Stephen T. Oh; Aaron T. Gerds; Vikas Gupta; John Catalano; Francisco Cervantes; Timothy Devos; Marek Hus; Jean Jacques Kiladjian; Ewa Lech-Maranda; Donal McLornan; Jeanne Palmer; Uwe Platzbecker; Jacek Treliński; Kazuya Shimoda; Rafe Donahue; Koenraad D’Hollander; Mark Kowalski; Srdan Verstovsek

doi:10.1080/10428194.2022.2043304

Momelotinib reduces transfusion requirements in patients with myelofibrosis

Ruben Mesa, Stephen T. Oh, Aaron T. Gerds, Vikas Gupta, John Catalano, Francisco Cervantes, Timothy Devos, Marek Hus, Jean Jacques Kiladjian, Ewa Lech-Maranda, Donal McLornan, Jeanne Palmer, Uwe Platzbecker, Jacek Treliński, Kazuya Shimoda, Rafe Donahue, Koenraad D’Hollander, Mark Kowalski, Srdan Verstovsek

Hematology/Oncology

Research output: Contribution to journal › Letter › peer-review

Original language	English (US)
Pages (from-to)	1718-1722
Number of pages	5
Journal	Leukemia and Lymphoma
Volume	63
Issue number	7
DOIs	https://doi.org/10.1080/10428194.2022.2043304
State	Published - 2022

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.1080/10428194.2022.2043304

Cite this

Mesa, R., Oh, S. T., Gerds, A. T., Gupta, V., Catalano, J., Cervantes, F., Devos, T., Hus, M., Kiladjian, J. J., Lech-Maranda, E., McLornan, D., Palmer, J., Platzbecker, U., Treliński, J., Shimoda, K., Donahue, R., D’Hollander, K., Kowalski, M., & Verstovsek, S. (2022). Momelotinib reduces transfusion requirements in patients with myelofibrosis. Leukemia and Lymphoma, 63(7), 1718-1722. https://doi.org/10.1080/10428194.2022.2043304

Mesa, R, Oh, ST, Gerds, AT, Gupta, V, Catalano, J, Cervantes, F, Devos, T, Hus, M, Kiladjian, JJ, Lech-Maranda, E, McLornan, D, Palmer, J, Platzbecker, U, Treliński, J, Shimoda, K, Donahue, R, D’Hollander, K, Kowalski, M & Verstovsek, S 2022, 'Momelotinib reduces transfusion requirements in patients with myelofibrosis', Leukemia and Lymphoma, vol. 63, no. 7, pp. 1718-1722. https://doi.org/10.1080/10428194.2022.2043304

@article{8b5798594eb849e6beec685751827228,

title = "Momelotinib reduces transfusion requirements in patients with myelofibrosis",

author = "Ruben Mesa and Oh, {Stephen T.} and Gerds, {Aaron T.} and Vikas Gupta and John Catalano and Francisco Cervantes and Timothy Devos and Marek Hus and Kiladjian, {Jean Jacques} and Ewa Lech-Maranda and Donal McLornan and Jeanne Palmer and Uwe Platzbecker and Jacek Treli{\'n}ski and Kazuya Shimoda and Rafe Donahue and Koenraad D{\textquoteright}Hollander and Mark Kowalski and Srdan Verstovsek",

note = "Funding Information: Momelotinib is sponsored by Sierra Oncology. Editorial support was provided by Impact Communication Partners, Inc. Funding Information: This work was funded by Sierra Oncology, Inc. Momelotinib is sponsored by Sierra Oncology. Editorial support was provided by Impact Communication Partners, Inc.",

year = "2022",

doi = "10.1080/10428194.2022.2043304",

language = "English (US)",

volume = "63",

pages = "1718--1722",

journal = "Leukemia and Lymphoma",

issn = "1042-8194",

publisher = "Informa Healthcare",

number = "7",

}

TY - JOUR

T1 - Momelotinib reduces transfusion requirements in patients with myelofibrosis

AU - Mesa, Ruben

AU - Oh, Stephen T.

AU - Gerds, Aaron T.

AU - Gupta, Vikas

AU - Catalano, John

AU - Cervantes, Francisco

AU - Devos, Timothy

AU - Hus, Marek

AU - Kiladjian, Jean Jacques

AU - Lech-Maranda, Ewa

AU - McLornan, Donal

AU - Palmer, Jeanne

AU - Platzbecker, Uwe

AU - Treliński, Jacek

AU - Shimoda, Kazuya

AU - Donahue, Rafe

AU - D’Hollander, Koenraad

AU - Kowalski, Mark

AU - Verstovsek, Srdan

N1 - Funding Information: Momelotinib is sponsored by Sierra Oncology. Editorial support was provided by Impact Communication Partners, Inc. Funding Information: This work was funded by Sierra Oncology, Inc. Momelotinib is sponsored by Sierra Oncology. Editorial support was provided by Impact Communication Partners, Inc.

PY - 2022

Y1 - 2022

UR - http://www.scopus.com/inward/record.url?scp=85126142199&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85126142199&partnerID=8YFLogxK

U2 - 10.1080/10428194.2022.2043304

DO - 10.1080/10428194.2022.2043304

M3 - Letter

C2 - 35255234

AN - SCOPUS:85126142199

SN - 1042-8194

VL - 63

SP - 1718

EP - 1722

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

IS - 7

ER -

Momelotinib reduces transfusion requirements in patients with myelofibrosis

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this